NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit

Rhea-AI Summary

NewAmsterdam Pharma (Nasdaq: NAMS) said its CFO Ian Somaiya and EVP Matthew Philippe will take part in a virtual fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on Wednesday, February 11, 2026 at 8:30 a.m. ET.

A live webcast will be available via the company investor relations site and an archived replay will be posted after the event.

Key Figures

Conference date: February 11, 2026 Conference time: 8:30 a.m. ET

2 metrics

Conference date February 11, 2026 Date of Guggenheim Emerging Outlook: Biotech Summit fireside chat

Conference time 8:30 a.m. ET Scheduled start time of virtual fireside chat

Market Reality Check

Price: $21.41 Vol: Volume 611,360 is slightl...

normal vol

$21.41 Last Close

Volume Volume 611,360 is slightly below the 20-day average of 658,460 (rel. volume 0.93). normal

Technical Price at $32.99 is trading above the 200-day MA of $27.62 and 21.45% below the 52-week high.

Peers on Argus

Peers show mixed moves: RARE -0.48%, VKTX -3.26%, while MLYS +2.17%, APLS +3.64%...

Peers show mixed moves: RARE -0.48%, VKTX -3.26%, while MLYS +2.17%, APLS +3.64%, CRNX +1.24%. This dispersion suggests today’s +4.5% move in NAMS is more stock-specific than sector-driven.

Historical Context

5 past events · Latest: Jan 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 09	Strategic/cash update	Positive	-4.0%	Outlined 2025 progress, 2026 priorities, and year-end cash position.
Jan 05	Inducement grants	Neutral	+1.6%	Inducement stock options for a new hire under 2024 Inducement Plan.
Dec 05	Inducement grants	Neutral	+1.4%	Option grants to two non‑executive hires under 2024 Inducement Plan.
Nov 25	Investor conferences	Neutral	+2.9%	Participation in three early December 2025 healthcare investor conferences.
Nov 07	Inducement grants	Neutral	+6.0%	Inducement option grant to a non‑executive new hire under Nasdaq rules.

Pattern Detected

Recent news has mostly been operational or administrative, with one notable case where seemingly positive strategic and cash updates coincided with a negative price reaction.

Recent Company History

Over the past few months, NewAmsterdam’s news flow has focused on strategic updates, equity compensation, and investor outreach. On Jan 9, 2026, the company highlighted 2025 achievements, 2026 priorities, and year-end cash of about $729M, yet shares fell 3.99%. Several Nasdaq Rule 5635(c)(4) inducement grants in late 2025 and early 2026 saw modest positive reactions. A December 2025 investor conference announcement was followed by a 2.87% gain, giving context for today’s Guggenheim conference appearance news.

Market Pulse Summary

This announcement highlights NewAmsterdam’s participation in the Guggenheim Emerging Outlook: Biotec...

Analysis

This announcement highlights NewAmsterdam’s participation in the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026, continuing a pattern of active investor outreach seen in prior conference appearances. The company previously outlined 2026 priorities for obicetrapib and reported year-end cash of about $729M. Recent Form 4 filings show equity awards and some tax-related and discretionary sales. Investors may watch future clinical, regulatory, and financial updates to gauge how this communication strategy supports the broader development and launch plans.

Key Terms

cardiovascular disease, low-density lipoprotein cholesterol, ldl-c, investor relations

4 terms

cardiovascular disease medical

"developing oral, non-statin medicines for patients at risk of cardiovascular disease"

A group of conditions that affect the heart and blood vessels, such as heart attacks, strokes and clogged arteries. Think of the cardiovascular system as a body’s plumbing and engine: when pipes narrow or the pump fails, treatment, devices and long-term care become necessary. Investors watch these diseases because their prevalence drives demand for drugs, devices and services, influences healthcare costs and insurer payouts, and affects workforce productivity and regulatory risk.

low-density lipoprotein cholesterol medical

"with elevated low-density lipoprotein cholesterol (“LDL-C”)"

A form of cholesterol carried in the blood that tends to deposit fatty material on artery walls, often called “bad” cholesterol; think of LDL as delivery trucks that sometimes drop sticky cargo along the body’s highways. Investors monitor LDL because drugs, medical devices, and diagnostic tests that change LDL levels or how they’re managed can drive healthcare spending, regulatory approvals, and company earnings, affecting valuations and risk in health-related businesses.

ldl-c medical

"with elevated low-density lipoprotein cholesterol (“LDL-C”)"

LDL-C stands for low-density lipoprotein cholesterol, the portion of cholesterol carried in the blood by LDL particles that is commonly linked to buildup of plaque in arteries—think of it like sticky debris that can clog pipes. Investors care because changes in LDL-C are a key measure used by regulators and clinicians to judge the effectiveness of cardiovascular drugs and devices, shape insurance coverage, and influence market demand for treatments that lower heart attack and stroke risk.

investor relations financial

"through the investor relations section of the NewAmsterdam Pharma website"

Investor relations is the communication process between a company and its current or potential investors. It involves sharing information about the company's performance, strategies, and outlook to help investors make informed decisions. Effective investor relations build trust and transparency, similar to a clear conversation between a business and someone considering investing, ensuring both parties understand each other's interests and expectations.

AI-generated analysis. Not financial advice.

NAARDEN, The Netherlands and MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a virtual fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on Wednesday, February 11, 2026 at 8:30 a.m. ET.

A live webcast of the fireside chat will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcast, an archived replay will be available on the Company’s website.

About NewAmsterdam

NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com

Media Contact
Real Chemistry on behalf of NewAmsterdam
Christian Edgington
P: 1-513-310-6410
cedgington@realchemistry.com

Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
austin.murtagh@precisionaq.com

FAQ

When will NewAmsterdam Pharma (NAMS) present at the Guggenheim Emerging Outlook: Biotech Summit?

NewAmsterdam will present on February 11, 2026 at 8:30 a.m. ET. According to the company, the presentation is a virtual fireside chat featuring CFO Ian Somaiya and EVP Matthew Philippe and is open via webcast to investors.

How can investors watch the NewAmsterdam Pharma (NAMS) fireside chat on February 11, 2026?

Investors can watch via a live webcast on the company investor relations website. According to the company, the live stream will be on the IR site and an archived replay will be available afterward.

Who from NewAmsterdam Pharma (NAMS) will speak at the Guggenheim biotech summit?

The speakers are CFO Ian Somaiya and EVP, Head of Investor Relations Matthew Philippe. According to the company, they will participate in a virtual fireside chat discussing recent developments and investor topics.

Will NewAmsterdam Pharma (NAMS) post a replay of the February 11, 2026 presentation?

Yes, an archived replay will be posted on the company website after the live event. According to the company, the replay will be available in the investor relations section following the webcast.

What topics are NewAmsterdam Pharma (NAMS) likely to address at the Guggenheim biotech summit?

The event will focus on company developments and investor relations topics rather than financial filings. According to the company, speakers will discuss clinical progress and corporate updates in a fireside chat format.